Qingketan^® Tedizolid Phosphate Tablets are a second-generation oxazolidinone antibiotic, used to treat acute bacterial skin and soft tissue infections (ABSSSI) caused by the following Gram-positive bacteria: Staphylococcus aureus (including Methicillin-resistant Staphylococcus aureus [MRSA] and Methicillin-sensitive Staphylococcus aureus [MSSA] isolates), Streptococcus pyogenes, Enterococcus faecalis, Streptococcus anginosus group (including Streptococcus pyogenes, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecium.

Qingketan^® Tedizolid Phosphate Tablets were launched in September 2023. They are characterized by strong antibacterial activity, high tissue penetration, clear clinical efficacy, low risk of resistance, and minimal drug interactions, making them an ideal choice for treating Gram-positive bacterial infections.